Endocrinology Today—July 7, 2026

This week’s Endocrinology update highlights regulatory approvals, chronic disease initiatives, advances in diabetes care, emerging screening technologies, and new evidence shaping long-term disease management.

In Today’s Newsletter

Dive deeper

💊 CinnaGen Zandoriah EU authorization [1] [EU • 03 Jul 2026]

https://natlawreview.com/press-releases/european-commissions-approval-cinnagens-teriparatide-signals-new-phase
Context: Zandoriah (CinnaGen; teriparatide biosimilar to Forsteo) is designed to treat adult osteoporosis.
Key point: European Commission granted centralized marketing authorization across EU27, Iceland, Liechtenstein, and Norway.
Implication: Introduces competition that may affect pricing and formulary access.

🤝 Vietnam hypertension and diabetes initiative [2] [Vietnam • 03 Jul 2026]

https://vietnamnews.vn/society/1784727/partners-sign-initiative-to-enhance-prevention-of-hypertension-and-diabetes-in-viet-nam.html
Context: Vietnam Ministry of Health MSA, Servier Vietnam, and multi-sector partners signed a 2026–30 chronic disease initiative.
Key point: The program aims for at least 50% of patients with hypertension and diabetes to meet treatment targets by 2030.
Implication: May expand screening, initiation, and follow-up at scale.

🫁 MannKind Afrezza pediatric T1D grant [3] [23 Jun 2026]

https://finance.yahoo.com/healthcare/articles/mannkind-mnkd-receives-grant-breakthrough-131159744.html
Context: INHALE-1ST will evaluate Afrezza (MannKind; inhaled insulin) with daily injectable basal insulin in ages 10–17.
Key point: Breakthrough T1D awarded a grant to support the safety and efficacy trial in newly diagnosed pediatric type 1 diabetes.
Implication: Signals pipeline investment and modality expansion.

📟 Tandem-Abbott CGM-pump compatibility launch [4] [01 Jul 2026]

https://www.businesswire.com/news/home/20260701506287/en/Tandem-Diabetes-Care-Launches-tslim-X2-Insulin-Pump-Compatibility-with-Abbott-FreeStyle-Libre-3-Plus-Sensor-in-Five-International-Markets
Context: t X2 (Tandem Diabetes Care) with Control-IQ+ now connects to Abbott FreeStyle Libre 3 Plus.
Key point: Compatibility launched in the UK, Switzerland, Sweden, Finland, and Italy, with more markets expected in 2026.
Implication: May expand screening, initiation, and follow-up at scale.

🩺 NICE PMOS draft guideline [5] [UK • 01 Jul 2026]

https://www.nice.org.uk/news/articles/nice-recommends-annual-review-for-pmos-in-new-draft-guideline-aimed-at-improving-diagnosis-and-care
Context: NICE published draft UK guidance for polyendocrine metabolic ovarian syndrome, formerly known as PCOS.
Key point: The draft recommends earlier diagnosis and annual review for symptoms, medicines, and long-term risks.
Implication: May expand screening, initiation, and follow-up at scale.

👁️ Reti-Pioneer AI retinal disease screening [6] [China • 29 Jun 2026]

https://medicalxpress.com/news/2026-06-ai-analyses-eye-scans-diseases.html
Context: Reti-Pioneer uses AI to analyze retinal images for diabetes, hypertension, high cholesterol, gout, osteoporosis, and thyroid disease.
Key point: A Nature Medicine study reports rapid screening using fundus-camera images, primarily in Chinese primary care centers.
Implication: May expand screening, initiation, and follow-up at scale.

🧬 Metformin adherence and polyneuropathy risk [7] [Taiwan • 29 Jun 2026]

https://www.neurologyadvisor.com/news/metformin-adherence-polyneuropathy-risk-type-2-diabetes/
Context: Investigators analyzed TriNetX Global Collaborative Network data and validated trends in Taiwan insurance data.
Key point: Long-term adherence to second-line metformin was associated with lower diabetic polyneuropathy risk in type 2 diabetes.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

💊 Renata Thyrox European approvals [8] [EU • 01 Jul 2026]

https://www.industryinsiderbd.com/article/renatas-thyrox-wins-approval-in-six-european-countries
Context: Thyrox (Renata; levothyroxine sodium) is used for hypothyroidism and other thyroid disorders.
Key point: Renata received approvals under the EU Decentralized Procedure in Ireland, Germany, Italy, Poland, Portugal, and Malta.
Implication: Introduces competition that may affect pricing and formulary access.

Why it matters

European endocrine access stories clustered around biosimilars, thyroid therapy, and diabetes technology.
Vietnam’s 2026–30 initiative shows chronic disease management moving toward multi-stakeholder, digitally enabled systems.
NICE’s PMOS draft guideline links reproductive, metabolic, cardiovascular, and mental health monitoring in routine care.
AI retinal screening and metformin adherence data highlight prevention, earlier identification, and longitudinal risk management.
Device interoperability remains a commercial lever in automated insulin delivery.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Endocrinology archive on our research hub page.

FAQ

What did the European Commission authorize for CinnaGen?

The European Commission authorized Zandoriah, CinnaGen’s teriparatide biosimilar to Forsteo, for adult osteoporosis across EU27 plus Iceland, Liechtenstein, and Norway. [1]

What is the goal of the Vietnam hypertension and diabetes initiative?

The 2026–30 program aims to strengthen prevention, treatment, and management, including a target for at least 50% of patients to meet treatment goals by 2030. [2]

What is MannKind studying with Breakthrough T1D support?

MannKind’s INHALE-1ST trial will evaluate Afrezza inhaled insulin with daily basal insulin in newly diagnosed pediatric type 1 diabetes, ages 10–17. [3]

Where did Tandem launch FreeStyle Libre 3 Plus compatibility?

Tandem launched t X2 compatibility with Abbott FreeStyle Libre 3 Plus in the UK, Switzerland, Sweden, Finland, and Italy. [4]

What does the NICE PMOS draft guideline recommend?

NICE recommends earlier diagnosis and an annual review covering symptoms, medicines, and long-term health risks such as diabetes and cardiovascular disease. [5]

What did the metformin adherence study find?

In observational analyses, metformin adherence was associated with reduced diabetic polyneuropathy risk in type 2 diabetes; interpretation depends on design and confounding control. [7]

Entities / Keywords

CinnaGen, Zandoriah, teriparatide, Forsteo, osteoporosis, biosimilar, European Commission
Vietnam Ministry of Health, Medical Service Administration, Servier Vietnam, hypertension, diabetes, NCD management
MannKind, Afrezza, Breakthrough T1D, INHALE-1ST, pediatric type 1 diabetes, inhaled insulin
Tandem Diabetes Care, t X2, Control-IQ+, Abbott, FreeStyle Libre 3 Plus, CGM, automated insulin delivery
NICE, polyendocrine metabolic ovarian syndrome, PMOS, PCOS, annual review, early diagnosis
Reti-Pioneer, AI retinal imaging, fundus camera, diabetes screening, hypertension, osteoporosis, thyroid disease
Metformin, type 2 diabetes, diabetic polyneuropathy, TriNetX, Taiwan National Health Insurance Research Database
Renata, Thyrox, levothyroxine sodium, hypothyroidism, EU Decentralized Procedure